Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1157-1167

  Wright, D Hamish ^a   Herman, Gary A ^a   Maes, Andrea ^a   Liu, Qi ^a   Johnson Levonas, Amy O ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Sitagliptin; Warfarin

Indexed keywords

SITAGLIPTIN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HAND PARESTHESIA; HEADACHE; HUMAN; HYPOGLYCEMIA; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MALE; MULTIPLE DRUG DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN;

ADOLESCENT; ADULT; ANTICOAGULANTS; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; PYRAZINES; TRIAZOLES; WARFARIN;

EID: 70349479419     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009341653     Document Type: Article

References (32)

1. Januvia (sitagliptin) tablets [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc ; 2007.
2. Deacon CF, Ahren B., Holst JJ Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes ? Expert Opin Investig Drugs. 2004 ; 13: 1091-1102.
3. Holst JJ, Deacon CF Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998 ; 47: 1663-1670.
4. Aschner P., Kipnes MS, Lunceford JK, Sanchez M., Mickel C., Williams-Herman DE Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 ; 29: 2632-2637.
5. Bergman AJ, Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006 ; 28: 55-72.
6. Herman GA, Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 ; 78: 675-688.
7. Herman GA, Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 ; 91: 4612-4619.
8. Raz I., Chen Y., Wu M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008 ; 24: 537-550.
9. Mistry GC, Bergman AJ, Luo WL, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol. 2007 ; 47: 159-164.
10. Herman GA, Bergman A., Yi B., Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006 ; 22: 1939-1947. (Pubitemid 44663399)
11. Mistry GC, Bergman AJ, Zheng W., et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008 ; 66: 36-42.
12. Coumadin tablets/coumadin for injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb ; 2007.
13. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991 ; 324: 1865-1875.
14. Hirsh J., Dalen J., Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 ; 119: 8S - 21S.
15. Kirkwood TB Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost. 1983 ; 49: 238-244.
16. Johnston M., Harrison L., Moffat K., Willan A., Hirsh J. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. J Lab Clin Med. 1996 ; 128: 214-217.
17. Kimmel SE Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008 ; 9: 677-686.
18. Serlin MJ, Breckenridge AM Drug interactions with warfarin. Drugs. 1983 ; 25: 610-620.
19. Herman D., Locatelli I., Grabnar I., et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005 ; 5: 193-202.
20. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole: II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos. 1996 ; 24: 422-428.
21. Kaminsky LS, Zhang ZY Human P450 metabolism of warfarin. Pharmacol Ther. 1997 ; 73: 67-74.
22. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992 ; 5: 54-59.
23. Trager WF, Lewis RJ, Garland WA Mass spectral analysis in the identification of human metabolites of warfarin. J Med Chem. 1970 ; 13: 1196-1204.
24. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005 ; 44: 1227-1246.
25. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol. 2003 ; 43: 443-469.
26. US Food and Drug Administration (FDA), Department of Health and Human Services Center for Drug Evaluation and Research. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD: FDA ; 1999.
27. Van Hecken A., Depre M., Verbesselt R., et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1999 ; 39: 495-500.
28. Anderson DM, Shelley S., Crick N., Buraglio M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002 ; 42: 1358-1365.
29. He YL, Sabo R., Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007 ; 23: 1131-1138.
30. Ouellet D., Bramson C., Carvajal-Gonzalez S., et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006 ; 61: 741-745.
31. Soon D., Kothare PA, Linnebjerg H., et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006 ; 46: 1179-1187.
32. Zhou H., Patat A., Parks V., Buckwalter M., Metzger D., Korth-Bradley J. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol. 2004 ; 44: 543-550. (Pubitemid 38509724)